Combination Therapy for Cancer Treatment

For drug dosage and route of administration, we followed reported methods [12 (link)]. In brief, cyclophosphamide (Cy) (Tocris Bioscience) was used at a final concentration of 100 mg/Kg and administrated intraperitoneally (i.p.) twice, each dose one week apart. When LCL161 (Chemietek) was used, 50 mg/Kg LCL161 was administrated via the oral gavage (o.g.) route. The checkpoint inhibitor α-PD-1 (BioXCell) was administrated intraperitoneally (i.p.) at a final concentration of 10 mg/Kg. One week after cancer implantation, both LCL161 and α-PD-1 were administrated on days 1, 4, 8, 11 as described in Figure 4A.

Free full text: Click here

Villa N.Y., Rahman M.M., Mamola J., Sharik M.E., de Matos A.L., Kilbourne J., Lowe K., Daggett-Vondras J., D'Isabella J., Goras E., Chesi M., Bergsagel P.L, & McFadden G. (2022). Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma. Oncotarget, 13, 490-504.

Publication 2022

cyclophosphamide LCL161 α-PD-1

Cancer Checkpoint Cyclophosphamide Drug Gavage Implantation Lcl161

Corresponding Organization : Arizona State University

Other organizations : Emory University, Mayo Clinic in Arizona

Top 5 similar protocols

Variable analysis

independent variables

Cyclophosphamide (Cy) at a final concentration of 100 mg/Kg, administered intraperitoneally (i.p.) twice, each dose one week apart
LCL161 at a concentration of 50 mg/Kg, administered via the oral gavage (o.g.) route
Checkpoint inhibitor α-PD-1 at a final concentration of 10 mg/Kg, administered intraperitoneally (i.p.)
LCL161 and α-PD-1 administered on days 1, 4, 8, 11 after cancer implantation

dependent variables

Measured outcomes not explicitly mentioned

control variables

Positive and negative controls not explicitly mentioned

controls

No positive or negative controls were explicitly mentioned in the provided information.

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!